Atazanavir, Alone or in Combination with Ritonavir, Inhibits SARS-CoV-2 Replication and Proinflammatory Cytokine Production-Reference-Cited by-同舟云学术

Atazanavir, Alone or in Combination with Ritonavir, Inhibits SARS-CoV-2 Replication and Proinflammatory Cytokine Production

Published:2020-09-21 Issue:10 Volume:64 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Fintelman-Rodrigues Natalia¹²,Sacramento Carolina Q.¹²,Ribeiro Lima Carlyle²,Souza da Silva Franklin³²,Ferreira André C.¹⁴²,Mattos Mayara¹²,de Freitas Caroline S.¹²,Cardoso Soares Vinicius¹,da Silva Gomes Dias Suelen¹,Temerozo Jairo R.⁵⁶,Miranda Milene D.⁷^ORCID,Matos Aline R.⁷,Bozza Fernando A.⁸⁹,Carels Nicolas²,Alves Carlos Roberto³,Siqueira Marilda M.⁷,Bozza Patrícia T.¹^ORCID,Souza Thiago Moreno L.¹²^ORCID

Affiliation:

1. Laboratório de Imunofarmacologia, Instituto Oswaldo Cruz (IOC), Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, Rio de Janeiro, Brazil

2. National Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDPN), Center for Technological Development in Health (CDTS), Fiocruz, Rio de Janeiro, Rio de Janeiro, Brazil

3. Laboratório de Biologia Molecular e Doenças Endêmicas, IOC, Fiocruz, Rio de Janeiro, Rio de Janeiro, Brazil

4. Universidade Iguaçu, Nova Iguaçu, Rio de Janeiro, Brazil

5. Laboratório de Pesquisas sobre o Timo, IOC, Fiocruz, Rio de Janeiro, Rio de Janeiro, Brazil

6. National Institute for Science and Technology on Neuroimmunomodulation (INCT/NIM), IOC, Fiocruz, Rio de Janeiro, Rio de Janeiro, Brazil

7. Laboratório de Vírus Respiratório e do Sarampo, IOC, Fiocruz, Rio de Janeiro, Rio de Janeiro, Brazil

8. Instituto Nacional de Infectologia Evandro Chagas, Fiocruz, Rio de Janeiro, Rio de Janeiro, Brazil

9. Instituto D’or de Pesquisa e Ensino, Rio de Janeiro, Rio de Janeiro, Brazil

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is already responsible for far more deaths than previous pathogenic coronaviruses (CoVs) from 2002 and 2012. The identification of clinically approved drugs to be repurposed to combat 2019 CoV disease (COVID-19) would allow the rapid implementation of potentially life-saving procedures. The major protease (Mpro) of SARS-CoV-2 is considered a promising target, based on previous results from related CoVs with lopinavir (LPV), an HIV protease inhibitor.

Funder

Inova Fiocruz

MCTI | Conselho Nacional de Desenvolvimento Científico e Tecnológico

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior

Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00825-20

Reference58 articles.

1. The Molecular Biology of Coronaviruses

2. Origin and evolution of pathogenic coronaviruses

3. Identifying SARS-CoV-2-related coronaviruses in Malayan pangolins

4. World Health Organization. 2020. Middle east respiratory syndrome coronavirus (MERS-CoV). https://www.who.int/emergencies/mers-cov/en/. Accessed 24 July 2020.

5. World Health Organization. 2020. Severe acute respiratory syndrome (SARS). https://www.who.int/health-topics/severe-acute-respiratory-syndrome. Accessed 24 July 2020.

Cited by 99 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Taming the storm: potential anti-inflammatory compounds targeting SARS-CoV-2 MPro;Inflammopharmacology;2024-07-24

2. Plausible mechanism of drug resistance and side-effects of COVID-19 therapeutics: a bottleneck for its eradication;DARU Journal of Pharmaceutical Sciences;2024-07-19

3. Statine-based peptidomimetic compounds as inhibitors for SARS-CoV-2 main protease (SARS-CoV‑2 Mpro);Scientific Reports;2024-04-18

4. COVID-19 drug discovery and treatment options;Nature Reviews Microbiology;2024-04-15

5. Screening for Active Compounds of Acorus calamus against SARS-CoV-2 Viral Protease and Mechanism Prediction;Pharmaceuticals;2024-03-01